ArticleAging clinical and experimental research2026
Glycemic control in the context of frailty: a mortality risk assessment in older diabetic patients.
Article in Aging clinical and experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlycemia control in older diabetic adults is complicated by uncertainty regarding how intensive glycemic control should be, particularly in those with frailty. This study investigated the association between HbA1c levels and all-cause mortality, assessing the modifying effect of frailty. METHODS/
designThis retrospective study used Hong Kong hospitalization data (2012–2021) for older adults. Patients with first-recorded diabetes during 2014–2020 were classified as index cases. Frailty was evaluated using the Hospital Frailty Risk Score (HFRS), derived from two years of hospitalization diagnoses before the index diabetes and categorized as follows: no (HFRS = 0), mild (HFRS <5), and moderate andsevere frailty (HFRS ≥5). Glycemic control was assessed via time-weighted mean HbA1c and early variability of the first three measurements. The relationship between HbA1c, variability, and mortality was examined using multivariable Cox regression, with nonlinear relationships modeled via restricted cubic splines.
resultsA J-shaped curve was observed for HbA1c-mortality association (p-nonlinearity <0.001), with increased risk at low/high extremes, significantly influenced by frailty (p-interaction <0.001). In non-frail patients, lower mortality was noted across an HbA1c range of 5.4%–10.5%, with a minimum at 7.8% (HR = 0.59, 95% CI: 0.56–0.61). For those with moderate andsevere frailty, the safety zone narrowed to 6.1%–9.3%, with a nadir at 7.7% (HR = 0.73, 95% CI: 0.68–0.79). Early glycemic variability significantly affected mortality risk only in non-frail individuals.
conclusionFrailty alters the mortality risk associated with glycemic control, highlighting the need for frailty-stratified management strategies in older diabetic adults to optimize health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.